Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Ongoing Research Efforts in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.

Post-Surgery Atezolizumab Fails to Provide Benefit in Combination With Chemotherapy for TNBC

March 23rd 2024

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer.

Dr Borgen on the Debate Over Routine MRI Testing in Early-Stage Breast Cancer

March 22nd 2024

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Dr Kuerer on Advancements in Neoadjuvant Systemic Therapies in Breast Cancer

March 22nd 2024

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer

March 22nd 2024

Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.

FDA Green Lights Fluorouracil Safety Label Update Regarding Use in Patients With DPD Deficiency

March 21st 2024

The FDA has approved safety label changes for fluorouracil products to include information regarding the agent’s use in patients with DPD.

Factors for Consideration When Choosing Among Options for Patients with ET-resistant ER+/HER2- mBC

March 21st 2024

Oncologists discuss considerations for systemic therapy selection beyond first-line endocrine-based regimens in recurrent hormone receptor-positive, HER2-low metastatic breast cancer, including use of additional endocrine therapy combinations, chemotherapy, and supportive care approaches.

Approaches to Mutation Testing for Patients With HR+/HER2-low mBC and ET-Resistant Disease

March 21st 2024

Laura Spring, MD, and Manali Bhave, MD, discuss considerations for systemic therapy selection in a patient with recurrent hormone receptor-positive, HER2-low breast cancer, including use of plasma and tissue genomic testing and endocrine therapy sequencing based on factors like prior response and ESR1 mutation status.

State of the Science Summit– Breast Cancer: Chaired by Rita Nanda, MD

March 21st 2024

State of the Science Summit– Breast Cancer: Chaired by Rita Nanda, MD

Dr Mahtani on Unique Challenges Women in Oncology Experience During Career Transitions

March 19th 2024

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Liquid Nitrogen–Based Cryoablation Leads to High RFS Rate in Low-Risk, Early-Stage Breast Cancer

March 19th 2024

Liquid nitrogen–based cryoablation elicited a 5-year local RFS rate of 96.39% in patients with low-risk, early-stage breast cancer.

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care

March 18th 2024

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

AE Management With Neratinib in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.

Unmet Needs in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.

Mutter Discusses Partial Breast Irradiation in Low-Risk Breast Cancer

March 15th 2024

Robert W. Mutter, MD, discusses the nuances of partial breast irradiation in early-stage breast cancer.

Advanced Radiation Techniques Could Aid in Cardiac Sparing in Lung, Breast, and Esophageal Cancer Treatment

March 15th 2024

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

Navigating Career Crossroads: Insights from Hope Rugo’s Journey as a Woman in Oncology

March 15th 2024

Hope S. Rugo, MD, draws on her own journey as a woman in oncology to provide insights on navigating career transitions and building support networks.

Graff Highlights the Importance of Perseverance and Self-Advocacy as a Woman in Oncology

March 15th 2024

Stephanie L. Graff, MD, shares her journey to becoming an oncologist, advice for work-life balance, and ways to confront gender bias in medicine.

State of the Science Summit - Breast and Lung Cancer: Chaired by Anne Favret, MD, and Samantha DiBenedetto, MD

March 15th 2024

State of the Science Summit - Breast and Lung Cancer: Chaired by Anne Favret, MD, and Samantha DiBenedetto, MD.